Physician profile
Young Seol
NPI 1700379203
$2,978.24
in general payments reported to CMS, 2019-2025
15 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $39.01 · 2021: $490 · 2022: $719 · 2023: $846 · 2024: $438 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,369.38 | 2022-2025 | Clareon, Hydrus Microstent, Argos |
| Glaukos Corporation | $373.37 | 2021-2022 | |
| Sight Sciences, INC. | $194.88 | 2023 | Omni Surgical System |
| Abbvie INC. | $166.52 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Omeros Corporation | $125.00 | 2021 | |
| Ocular Therapeutix, INC. | $119.98 | 2021 | |
| Oyster Point Pharma, INC. | $106.78 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $105.76 | 2022-2024 | Miebo, Prolensa, Vyzulta |
| Allergan, INC. | $99.99 | 2019 | |
| Sun Pharmaceutical Industries INC. | $96.73 | 2022-2023 | Cequa |
| Horizon Therapeutics Plc | $80.88 | 2023 | Tepezza |
| Carl Zeiss Meditec Cataract Technology INC. | $59.55 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $39.01 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.23 | 2022 | |
| Beaver-Visitec International, INC. | $18.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Seol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.